Session (CTI)

ISSUE: Three converging forces are reshaping pharmaceutical innovation — where it happens, who accesses it, and on what terms. Does Europe adequately recognise and reward innovation, and what are the consequences if not? Global pricing dynamics are sending complex signals to innovators. The US, long the anchor of pharmaceutical revenue, is introducing Most-Favored-Nation (MFN) pricing, adding further uncertainty. China's rapid emergence as a biopharmaceutical force illustrates what happens when an ecosystem deliberately rewards innovation. Now rivalling established leaders, China serves as a mirror — forcing Europe to question its positioning. Value assessment is deeply interconnected across markets, with decisions in one region rippling into others. Europe's environment — characterised by protracted timelines, fragmentation, and price erosion — risks sending negative signals to investors. Europe's policy reforms — including the HTA Regulation, Pharmaceutical Legislation, Biotech Act, and Critical Medicines Act — carry potential. But the test is whether patients, innovators, and investors experience them as a coherent signal valuing medical progress. This panel will explore what it will take for Europe to remain a place where innovation is genuinely sustained: where value is recognised, access is achieved, and investment follows. OVERVIEW: Introduction provided by Casper Paardekooper (moderator), introducing the panel and the Triple Challenge for Europe (10 min). Neil Grubert will share his views on global policy shifts and global pricing dynamics (12 min). Eelko den Breejen will share his views on Europe’s competitiveness and its positioning in the global innovation landscape from an industry perspective (12 min). Ferenc Marofka will shed light on the latest developments in EU policy and share his views on the expected impacts of ongoing and upcoming reforms (12 min). Time is allowed for audience questions and a panel discussion (15 min). This session will benefit stakeholders in European market and patient access, either from a patient, industry or payer perspective.